‘India’s IT missed the leap’: Anupam Mittal flags AI threat after Sun Pharma’s big bet
Shark Tank India judge Anupam Mittal shared a LinkedIn post that sparked a fresh debate on India’s tech future, saying Sun Pharmaceutical Industries’ $11.75 billion acquisition of Organon & Co. is more than just a business deal but it signals that the country’s IT sector must evolve.
Mittal described the all-cash deal as a turning point for Sun Pharma, which has long been known for its generics business. “For two decades, Sun was India’s smartest generics player—wait for an American patent to expire, manufacture cheaper, and sell everywhere,” he wrote on LinkedIn.
